Is conflict of interest in our best interest? by Beyer, Thomas & Czernin, Johannes
EDITORIAL
Is conflict of interest in our best interest?
Thomas Beyer & Johannes Czernin
Published online: 30 March 2010
# The Author(s) 2010. This article is published with open access at Springerlink.com
From X-rays to being X-ed out
On 8 November 1895 Wilhelm Conrad Röntgen observed a
special type of radiation that was created from an electric
discharge passing through a vacuum tube. He labelled this
radiation “X-rays” using the mathematical designation for
something unknown. Through X-rays matter became
transparent, as so vividly demonstrated by the well-known
X-ray image of the hand of Röntgen’s wife. Röntgen, at the
time of his groundbreaking discovery was the Chair of
Physics at the University of Würzburg (1888–1900). He
had no financial affiliations with industry; instead he argued
with them over the costs for the vacuum tubes he used for
his experiments: “Ihre Röhren sind in der Tat sehr gut, aber
für meine Verhältnisse zu theuer,…Ich möchte mir deshalb
die Frage erlauben, ob Sie mir die Röhren nicht zu M[ark]
20 statt zu M[ark] 30 liefern könnten…Falls Sie auf meinen
Vorschlag eingehen, bitte ich Sie mir für die zwei bereits
verbrauchten Röhren 4 andere gleicher Qualität zu
schicken…Hochachtungsvoll” (Your tubes are indeed very
good but too expensive for me. ... Therefore, I would like to
ask whether you could provide me with the tubes at a price
of 20 Marks instead of 30 Marks ... Should you be
agreeable, I like you to replace my two already used tubes
with four other tubes of similar quality ... Sincerely) [1].
Soon after Röntgen’s invention, made solely in the
realms of academic research, several manufacturers offered
X-ray tubes and helped disseminate X-ray imaging tech-
nologies among medical professionals. Röntgen does not
appear to have benefited financially from his invention. The
discovery of the X-rays and their subsequent use in various,
primarily medical set-ups paved the path to non-invasive
diagnosis. Thus, the non-invasively invisible became visible
and by that the world of medicine was changed forever.
Taking X-ray imaging a step further, Godfrey Newbold
Hounsfield prototyped a workable tomographic transmis-
sion imaging device in 1968 [2]. Unlike Röntgen, Houns-
field was an industry-paid expert working at the Central
Research Laboratory for Electric and Musical Industry
(EMI) Ltd. in the UK since 1951. Subsequent to his in-
house research the first CT system was installed in October
1971 at the Atkinson Morley’s Hospital and the first patient
images were taken in 1972 [3]. Interestingly, the company
EMI did not realize the potential commercial impact of the
CT system and estimated a market need of 25 systems only.
By 1974 already 60 EMI CT systems were installed and by
1979 more than 1,000 CT from over 20 manufacturers were
installed and operational worldwide. Today the number of
clinical CT systems has exceeded 50,000. One may ask,
with Hounsfield’s roots in industry, is the value of his
invention reduced?
Next to CT other imaging modalities were developed at
the same time. The beginning of modern PET, for example,
dates back to the early 1970s, when Phelps and colleagues
at Washington University and, independently, researchers at
Brookhaven National Laboratories built the first prototypes
o far i n gd e s i g nP E Ts y s t e m[ 4, 5]. The first, and
subsequently successful approach, in particular, was joined
early on by EG&G ORTEC, an Oak Ridge-based spin-off
from Oak Ridge National Laboratories. The EG&G ORTEC
group provided expertise in detectors and coincidence
electronics and some nuclear instrumentation modules. A
prototype (PETT) was used in January 1974 for first PET-
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commercial PET unit in 1976 in Los Angeles, more than
1,000 PET-only were installed, again by several manufac-
turers. Thus, PET imaging, invented in academia but
developed in close collaboration between industry and
academia was made available to patients following the rapid
commercialization of the invention of this imaging concept.
Does this reduce the value of an invention that was
conceived in academia?
The history of single-modality tomographic imaging
indicates that a close collaboration of academia and industry
has fostered the fast dissemination of these imaging
technologies. Commercial adoption of academic ideas for
non-invasive imaging is further exemplified by the introduc-
tion of dual-modality PET/CT tomographs. The idea for
combining PET and CT originated in a clinically active
academic environment in Geneva and Pittsburgh [6]p r i o rt o
a grant application to the National Institute of Health (NIH)
in 1994 proposing to build a prototype of an integrated PET/
CT system. Of note, the grant application was supplemented
by a letter of support from Dr Ronald Nutt (CEO of CTI
PET Systems Inc, Knoxville, TN, USA). The PET/CT grant
was funded in 1995 and during the review it was ranked in
the top 1.4 percentile for that cycle of grant requests. Today,
PET/CT systems are offered by 6 manufacturers and more
than 5,000 PET/CT systems are installed worldwide. From
its conception PET/CT imaging was a collaborative and co-
funded effort between academia and industry.
Lately, combined PET/MRI imaging has become the
focus of attention in medical imaging [7]. Several academic
research teams have proposed PET/MR systems for animal
imaging since the mid-1990s [8]. Since 2008 several
companies have indicated a keen interest in exploring the
clinical potential of combining PET and MRI and a few
gave indications to develop fully integrated PET/MRI in the
near future [9]. While early methodological developments
are supported to a great extent by research grants in the US
(National Institutes of Health, NIH), EU (Framework
Programme, FP) and Germany (German Research Founda-
tion, DFG), early clinical deployment of PET/MR is driven
to a great extent by industry. Today, the first clinical PET/
MR prototypes are installed and being evaluated in
academic research institutions [10, 11]. In view of the
significant support by industry, are the inventions of multi-
modality imaging of less value? Do we have to prepare for
multi-morality when going multi-modality?
Framing recent discussions: scrutiny or unity?
Medical imaging technology development was almost
always initiated in academia based on a clinical need.
Then, in a second step, a commercial grade prototype or
beta product was created, almost always in collaboration
with industry [12], followed by safety and efficacy studies
and, lastly, by US Food and Drug Administration (FDA)
approval. One could even argue that the more complex the
imaging modality in pursuit, the greater the need for even
closer collaboration with industry for fast prototyping
and clinical adoption. In fact, the implementation of
state-of-the-art imaging in patient care and access to
modern technologies throughout the developed countries
is made possible only through industry-supported product
developments.
However, lately industry-academia relationships have
become the focus of attention with respect to discussions on
conflicts of interest (COI) and compliance guidelines. A
COI is considered a set of circumstances that creates a risk
that professional judgment or actions regarding a primary
interest will be unduly influenced by a secondary interest
[13]. COI and bias are ubiquitous. In medicine they may
have the potential to harm patients by introducing bias
towards existing or against novel diagnostics or therapeutics.
Competing interests may arise from financial, academic and
personal factors [14]. Potential COI may occur at many
levels in academia, industry and at their interception, in
public-private partnerships or with either academic or
industry experts changing sides.
Financial drivers of COI have received the most
attention as they are easily described. However, non-
financial drivers may be equally or more important. These
could relate, for example, to the competitive actions among
academicians when applying for scarce funding or compe-
tence awards. On a more personal level, experts could be
biased when reviewing applications for grants, positions or
manuscripts. These biases created from non-financial COI
are much more difficult to detect, measure or even prove,
but it seems obvious that neither industrial nor academic
experts are immune to these [15].
Potential COI in academia—how financial are they?
We currently lack an understanding of what collaborating
physicians and experts regard as appropriate or inappro-
priate benefits [16]. Nonetheless, we should avoid
classifying experts based on the origin of their paycheck
into “intrinsically malign” (i.e. big industry) and “noble
seekers” (i.e. academics) [14].
Public grants
Investigators compete for federal, national and international
public funding because they need to finance their research.
In many instances, funding levels are among the key
determinants for academic evaluations and success, and, as
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their research agendas under the whims of external funding
agencies” [15]. This intimate link between funding and
professional advances, in our view, can at least introduce a
bias in data collection and interpretation. Further, the fact
that few publications with “negative results” are published
should not argue against the quality of the studies. Finally,
the pressure exerted by academic institutions and funding
agencies to measure academic success by the accrued
number of impact points only lends itself to an obstructed
progression of academic innovation.
Self-referral practice
Clinically unsubstantiated self-referring practice is known
to be a key element in the rising number of imaging exams
and costs in health care systems worldwide [17]. While as
such this may be considered bad practice, at most it does
p o s et h er i s ko faC O I[ 18] when the self-referring
physician follows ownership interest under the auspices of
a professional organization. One may even argue that those
academic physicians with additional direct financial income
from seeing private patients benefit from academic research
that demonstrates the benefits of a particular diagnostic
method, such as PET, that is available only to those private
patients.
Academic organizations
Academic and professional organizations are not only
supported by membership fees. In fact, they frequently
generate their largest revenues through industry support.
This again introduces the potential for a COI. As a result
several associations have published transparency guidelines
that state their academic mission and detail their interaction
with non-academic partners.
Engaging in transparency guidelines is a prerequisite for
medical associations and for the public to acknowledge the
professional cooperation between all experts in this discipline.
However, publishing guidelines that prepare industry for
sponsorship of events or research grants on the one hand,
but stating that “in the case of clinical guidelines no experts
from industry or with any other commercial background may
be involved” represents an imbalanced perspective on public-
private partnerships [19].
Entrepreneurial faculty
Researchers in academia start or co-found companies to
translate and transfer their inventions to the market place.
This approach has several motivations [20]. The first one
would be that the inventors believe that their invention is
important and useful and that it, therefore, should be made
available to the public. A second important motivation is,
without any doubt, financial. In medicine achieving success
as both academic researcher and entrepreneur requires
intense dedication and commitment to excellence and the
will to have an impact on patient care [12]. Therefore, we
should be careful in portraying some people as less noble
than others simply because they also have a financial
interest. Nonetheless, the fact that academic researchers
follow, at least in part, a commercial path mandates full
transparency. Transparency can be achieved by declaring
and acting on a potential duality or COI.
Private grants and foundations
In view of scarce public funds many researchers turn to
foundations and private research funding agencies. Depending
on the amount of funding requested these agencies require
similar applications as public funding agencies. However,
frequently the first contact to these private funds is established
through high-level personal contacts and it would seem that
well-informed academic teams would have a benefit over
more inhibited, yet equally intellectual teams. Again, full
disclosure of the research support is required, not to
acknowledge the PI’s talent to obtain grant support but to
fully inform the reader and audience of the funding sources
for the work being presented.
Industry support
Researchers who have increasing difficulties obtaining
federal or public funds could gain considerable freedom
and independence for their academic programmes from
industry support. This is even better understood when
considering the often convoluted bureaucracy involved in
obtaining public funds and executing their investment in
personal and research group meetings [21]. Of course,
interactions between academia and industry do carry the risk
of abuse, corruption and scientific misconduct. However, this
risk also exists in publicly funded research as explained
above.
The need for intense industry-academia relationships
Current economy and drop in federal and public funds
We live in a time of great economic difficulties. The current
economic crisis affects all of us who are engaged in medical
imaging: industry, with decreasing revenues and profits,
and academia with steeply declining public funds for
medical research.
Resources need to be consolidated. Thus, it would seem
only natural for innovators and facilitators to partner (and
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(which they are assumed to have) to strengthen medical
diagnostic or therapeutic research. Industry-academia col-
laborations are probably the best way to support research
on every level in that area. One should also keep in mind
that many great scientists that were trained in academic
institutions are now industry leaders; and the reverse path
from industry to academia also exists.
Financial power of industry
Typically, various levels of collaboration between public
and private or academic and industrial partners exist. For
example, sizeable clinical trials of new drugs or imaging
probes cannot be conducted without strong support and
collaboration from industry. Such trials are either directly
funded by industry or can, in some instances, be indirectly
funded as is the case for the clinical trials network of the
Society of Nuclear Medicine, which are again frequently
funded by industry indirectly.
Imaging guidelines
Structured and standardized advice on when to use and how
to perform selected imaging procedures is essential for the
medical profession. Imaging guidelines help to shape and
promote the principles of a judicious choice of imaging
protocols. There is no obvious reason in excluding “all
those with potentially competing interests from expert
panels, and indeed, it may not be appropriate to do so,
but [it] is possible to manage the consensus process in such
a way that the effect of competing interests is minimized”
[14]. Why should industry experts, who may well have
gained expertise, such as in their previous academic career,
be denied access and active participation in guidelines
produced by an expert panel? The RECIST committee, for
example, consists of governmental and industry experts and
new guidelines on the use of RECIST, for better or worse,
are based on the input of both expert groups [22]. We
should move away from trading industry solely as an
eternal funding body while denying the fact that experts
with academic background may be employed by industry.
Experts can be on either side of the fence and may provide
well-justified expertise into a peer-reviewed process.
The need to translate
Academic institutions that are strapped for funds should be
highly interested in establishing substantial intellectual
property income. It is common practice today for univer-
sities to form technology transfer departments. However,
frequently these departments act as inhibitors rather than
catalysts of IP transfer [15]. Academic institutions are
poorly equipped to deal with technology transfer and need
to learn quickly how to best assist researchers to get their
inventions to the market. For example, as any business
expert knows, resisting exclusive licensing of a patent can
delay significantly the time to market of an academic
invention, particularly if an industry partner is at hand and
has already expressed interest in that patent.
Bothacademicandindustrypartnershaveakeeninterestin
advancing the field of medical imaging [12]. From the past it
is clear that for moving from an idea to a prototype, and
even more so from taking a prototype to a viable instrument
in clinical routine, partnering with industry is essential. An
alternative to partnering with an established vendor would be
to encourage academic entrepreneurs to create spin-off
companies. Spin-offs are sometimes considered as a more
suitable partner than a big industry partner although both
types of commercial entities work along the same principles
of efficient investment, healthy growth and revenue.
We are promoting that academia partners proactively
with industry in order to facilitate rapid translation of
promising inventions to the market. As shown throughout
history, financial interests and incentives are one proven
way to accelerate this translational process. Clearly inven-
tions that never reach the market cannot have a significant
impact on society.
Turning COI into dualities of interest
How canpotential conflicts bebestaddressed?The solutionis
not to create a new bureaucracy aiming at regulating the
placement of each industry-sponsored pencil, mouse pad or
coffee cup or objecting to the acceptance of industry-
supported meals, which frequently set the stage for exchanges
of ideas, or at least help create a level of inter-personal trust
between the collaborating sides. The onlyway toaddress COI
is complete disclosure of data and adherence to the concept of
peerreview. Inother words,the sourceoffundingisirrelevant
as long as data are disclosed, reviewed and can be verified.
So what are the practical implications for following a COI
policy adequately [14]? Here we discuss and propose a set of
remedies to address potential COI in public-private partner-
ships for advancing non-invasive imaging in medicine.
Disclosure
Honest disclosure of financial relationships to patients,
institutions and industry is an essential first step in
identifying and responding to COI. This must be comple-
mented by full data transparency. Many academic institu-
tions and global associations have established COI policies.
COI policies govern their or their member’s and employ-
ees’ interactions with industry. One example is the COI
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prohibiting public employees from personally benefiting at
the expense of the public interest, giving detailed descrip-
tions of five economic interests that may, upon careful
judgment, lead to a disqualification of the employee from
decision making processes [23].
Full transparency
Over the past 2 years most medical journals with high
impact factors had COI policies for their authors available
for public review [24]. For example, a new disclosure form
is suggested by Drazen et al. [25] that has been adopted by
all journals that are a member of the International
Committee of Medical Journal Editors (ICMJE). Therein
all authors submitting to any of these journals are asked to
disclose four types of information with respect to the
submitted manuscript. Similarly, this could be implemented
for oral presentations at conferences.
We should not forget that all scientific publications can be
authored by industry and/or academic experts. These pub-
lications are subject to independent examination by referees
who must be encouraged to critically examine the data and
claimspresented[15]. However, we should be aware that full
disclosure of COI of the authors, and thus their identity, may
create a non-financial COI with the referee that he/she
should willingly declare to the journal as well.
Transparency guidelines
Transparency guidelines should be put in place for acting
within national or international professional organizations.
They should be sensible and not overly prohibitive by
imposing numerous unilateral restrictions on experts of
academia or industry. We should keep in mind that industry-
academia relationships are not unethical per se, neither for the
individual nor for the institution; on the contrary, these
partnerships are extremely important, necessary and a moral
obligation for bringing together the best and brightest minds
inmedical researchtothe benefit oftaxpayers and consumers.
Then, experts and organizations and industry alike should
advocate partnerships to the public as mutually beneficial
platforms for advancing science and technology both in times
of crisis and prosperity.
Conclusion
Medical research should be mutually beneficial for patients,
industry and academia. Medical scientists envision their
inventions translated into the real patient world. All of us,
engaged in medical imaging, have an interest in seeing this
field grow. The more we specialize, the more we expand
into the unknown, the more we require funding and
sponsorship: for personnel, for instrumentation, for setting
up and conducting trials and test series, funding for creating
a prototype and funding for adopting a potential commer-
cial product to subsequent customer needs.
Funding can be obtained by academia from various
sources and expertise can be accrued by industry through
various internal and external sources. But both partners
must review their relationships with respect to accepting
industry merely as a source of plentiful funding (which they
are not) and considering academia solely as a source of paid
consultants (which they are not). Then, both partners will
benefit from a compliant partnership that helps transform
ideas into products.
We must make research and, if required, associated
product development transparent; this holds true for
funding sources from academia and government as well
as from industry.
We must render public-private partnerships active and
we should not shy away from drawing mutual benefits
from such partnerships. Academia, and perhaps more so,
national and international funding agencies must adopt
ways of spending time and funds efficiently, while
medical imaging industry must adopt strategies of
interdisciplinary communication as witnessed in academ-
ic and clinical partnerships.
The current reflex to COI discussions is frequently
Pavlovian: Collaborations are always perceived as a poten-
tial conflict. In our view, academia-industry collaborations
shouldbe considered an interest and not a conflict of interest.
It is in our interest and it is our moral obligation to
collaborate closely with industry to achieve rapid translation
of inventions into the clinic to the benefit of our patients. It is
perhaps time to analyse the damage done to health care by
institutional inertia and superficial morality.
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